MarketReportsOnline.com adds Global Excavator Market Report: 2016 Edition research to the fast growing manufacturing and construction sector business intelligence collection of its online data and market research library.

Pune, Maharashtra -- (SBWIRE) -- 04/13/2016 -- The key factors driving the growth of the excavator industry are rising urbanization, growth in construction expenditure and growing economy. Some of the noteworthy trends and developments of this industry are growing demand for fuel efficient excavator, introduction of new product and usage of high efficiency hydraulic fluids. However, the expansion of global excavator industry is hindered by high maintaining cost for hydraulic excavators and strict regulatory compliance imposed on producers.

The report "Global Excavator Market" provides an in-depth analysis of the excavator market along with a detailed study of the Chinese market. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The four major players in the industry, Caterpillar, Komatsu, Hitachi and Kobelco are being profiled.

Excavators are one of the major segments of construction equipment industry. These are used extensively in numerous fields ranging from construction of roads, building structures to mining and extraction of gold and diamonds. There are several types of excavators present in the industry, based on their size and machinery. Read more at http://www.marketreportsonline.com/464032.html .

There are many types of excavators, out of which demand of hydraulic excavators is discussed in the report. The demand of the hydraulic excavators declined worldwide. The decrease was mainly due to the downturn in hydraulic excavator demand in China, Japan and Asia & Oceania during 2015 despite continuing steady sales expansion in North America and Europe. Order a copy of this excavator market research at http://www.marketreportsonline.com/contacts/purchase.php?name=464032 .

Table of Contents

1. Excavator Market – An Introduction
1.1 Uses of Excavators
1.2 Types of Excavators
1.2.1 Compact Excavator
1.2.2 Dragline Excavator
1.2.3 Long Reach Excavator
1.2.4 Hydraulic Excavator
1.2.5 Power Shovel Excavator
1.2.6 Suction Excavator

2. Construction Equipment Market Analysis
2.1 Global Construction Equipment Sales by Volume
2.2 Global Construction Equipment Sales Share by Region
2.2.1 Europe Construction Equipment Sales by Volume
2.2.2 North America Construction Equipment Sales by Volume
2.2.3 Japan Construction Equipment Sales by Volume
2.2.4 China Construction Equipment Sales by Volume
2.2.5 India Construction Equipment Sales by Volume

3. Excavator Market Analysis
3.1 Global Excavator Market by Volume
3.1.1 North America Crawler Excavator Sales by Volume
3.1.2 EU Crawler Excavator Sales by Volume
3.1.3 EU Mini Excavator Sales by Volume

4. Hydraulic Excavator Market
4.1 Global Hydraulic Excavator Market by Volume
4.2 Global Hydraulic Excavator Market Share by Region
4.2.1 Japan Hydraulic Excavator Market by Volume
4.2.2 Europe Hydraulic Excavator Market by Volume
4.2.3 China Hydraulic Excavator Market by Volume
4.2.4 Asia and Oceania Hydraulic Excavator Market by Volume
4.2.5 North America Hydraulic Excavator Market by Volume
4.3 China Excavator Market
4.3.1 China Excavator Sales by Volume
4.3.2 China's Excavator Sales (Domestic vs. Export) by Volume
4.3.3 China Excavator Market Share by Size
4.4.4 China Excavator Market Share by Regional Players

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Urbanization
5.1.2 Accelerating Economic Growth
5.1.3 Increasing Construction Expenditure
5.2 Key Trends
5.2.1 Growing Demand for Fuel-Efficient Excavator
5.2.2 Usage of High Efficiency Hydraulic Fluids
5.2.3 Introduction of New Products
5.3 Challenges
5.3.1 High Maintenance Cost
5.3.2 Stringent Regulations

6. Competitive Landscape
6.1 Global Construction Equipment Market
6.2 China Excavator Market
6.2.1 China Excavator Market Share
6.2.2 China's Small-size Excavator Market Share
6.2.3 China's Medium-Size Excavator Market Share
6.2.4 China's Large-Size Excavator Market Share
6.2.5 China's Excavator Market Share 0-20 Tons
6.2.6 China's Excavator Market Share 20-40+ Tons
6.3 North America Crawler Excavator Market
6.3.1 North America Crawler Excavator Market Share
6.4 Japan Excavator Market
6.4.1 Japan Excavator Market Share
6.5 EU Crawler Excavator Market
6.5.1 EU Crawler Excavator Market Share
6.5.2 EU Mini Excavator Market Share

7. Company Profiles
7.1 Komatsu Ltd.
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Hitachi
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Caterpillar Inc.
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategies
7.4 Kobelco
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategies

List of Charts

Complete list available at http://www.marketreportsonline.com/464032-toc.html .

On a similar note, another research titled "Global Hydraulic Excavator Market: Trends and Opportunities (2014-2019)" provides an in-depth analysis of the global hydraulic excavator market (including crawler mounted hydraulic excavator) with detailed analysis of market sizing and growth, market share and economic impact of the industry. Detailed analysis of global hydraulic excavator resale and auction market is also presented in this report. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global hydraulic excavator industry has also been forecasted for the period 2014-2019, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. In addition to global hydraulic excavator market, detailed country/regional analysis of China, Japan, Europe, the US, India, Oceania and Asia is also provided. Further, key players of the hydraulic excavator industry like Caterpillar, Hitachi; Komatsu and Liebherr are also profiled with their financial information and respective business strategies. Read more at http://www.marketreportsonline.com/404219.html .

Explore more reports on manufacturing and construction markets at http://www.marketreportsonline.com/cat/manufacturing-market-research.html .

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

A new market research titled "The US Education Industry Report: 2015 Edition", now available with MarketReportsOnline.com, says industry has experienced several structural changes in the past few years and is reviving after slowdown from the Great Recession in the U.S.

Pune, Maharashtra -- (SBWIRE) -- 04/04/2016 -- Growth of the U.S. education industry is driven by several factors including increasing work participation of women in the U.S., rising post-secondary enrollment rates in the U.S and growing merger and acquisition activities in the industry. However, some other factors including declining population of children under five years of age and legal and regulatory issues tend to act as hindrances for growth of the given market.

The overall growth of US education market will be driven by rising responsiveness of people towards the benefits of early education, rising awareness of the advantages of higher education and growing demand for online teaching methods. The major trends in the industry include growth of educational content and technology, rising demand for digital textbooks, high penetration rate for U.S. post-secondary education sector, students shift towards online education and students dependence on family for higher education funding.

The U.S. education system follows a specific pattern where early childhood education is followed by primary school (Elementary school), middle school, secondary school (High school), and post-secondary (Tertiary) education. Education in the U.S. is provided both by public and private schools. Public education is universally required at the K-12 level, and is available at state colleges and universities for all students.

The report, "The U.S. Education Industry" analyzes the current prevailing condition of the industry along with its major segments including Pre-K, K-12, Post-Secondary and Corporate Training. The U.S. market along with specific dependence on other countries for growth including China, India, France and Germany is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth. Comprehensive table of contents and more on this research is available at http://www.marketreportsonline.com/442408-toc.html . Order a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=442408.

On a related note, another research titled "China Education Industry Report: 2016 Edition" says overall growth of the industry will be driven by rising responsiveness of people towards the benefits of early education and continuing education and growing demand for online teaching methods. The trends observed in China regarding the education industry are growing access to internet and declining rates of young population. While on one side, internet opens up the opportunities to grab overseas education, simultaneously it poses a threat to domestic educational institutions. Another challenge faced by the industry is declining rate of young population reflected by the fact that enrollments in primary and secondary education have been declining since 2007. The major players, TAL Education, TARENA International, China Distance Education Holding and New Oriental have being profiled and compared, along with their key financials and strategies for growth. Complete report is available at http://www.marketreportsonline.com/442408.html.

Explore more reports on public sector market at http://www.marketreportsonline.com/cat/government-market-research.html.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “HIV-1 Infection – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the HIV-1 Infection’s therapeutic pipeline.

Dallas, TX -- (SBWIRE) -- 11/06/2014 -- This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.

HIV-1 is the most common and pathogenic strain of the virus. Scientists divide HIV-1 into a major group (Group M) and two or more minor groups. Each group is believed to represent an independent transmission of SIV into humans (but subtypes within a group are not). A total of 39 ORFs are found in all six possible reading frames (RFs) of HIV-1 complete genome sequence, but only few of them are functional.

Complete Report Available
http://www.rnrmarketresearch.com/hiv-1-infection-pipeline-review-h2-2014-market-report.html

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

HIV-1 Infection - Companies Involved in Therapeutics Development:

AbbVie Inc., AlphaVax, Inc., AltraVax Inc., Amunix, Inc., Aphios Corporation, Argos Therapeutics, Inc., Bionor Pharma ASA, Biosantech SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Critical Outcome Technologies Inc., CytoDyn Inc., Enzo Biochem, Inc., FIT Biotech Oyj, GeneCure LLC, Gilead Sciences, Inc., GlaxoSmithKline plc, InnaVirVax SA, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Kaketsuken K.K., Koronis Pharma, Inc., Merck & Co., Inc., Mymetics Corporation, Myrexis, Inc., Oncovir, Inc., OyaGen Inc., Peregrine Pharmaceuticals, Inc., Pfizer Inc., Pharis Biotec GmbH, RFS Pharma, LLC, Spider Biotech, TaiMed Biologics Inc., Takara Bio Inc., THERAVECTYS SA, Tobira Therapeutics, Inc., United Biomedical, Inc., Valens Therapeutics, Inc., Vichem Chemie Research Ltd., ViiV Healthcare.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=235904

Scope:

-The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Reasons to buy:

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Develop strategic initiatives by understanding the focus areas of leading companies

-Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection

-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

-Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Infectious Diseases Therapeutics Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Schizophrenia – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Schizophrenia’s therapeutic pipeline.

Dallas, TX -- (SBWIRE) -- 11/05/2014 -- This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.

Schizophrenia is a mental disorder often characterized by abnormal social behavior and failure to recognize what is real. Common symptoms include false beliefs, unclear or confused thinking, auditory hallucinations, reduced social engagement and emotional expression, and inactivity. Diagnosis is based on observed behavior and the person's reported experiences.

Complete Report Available
http://www.rnrmarketresearch.com/schizophrenia-pipeline-review-h2-2014-market-report.html

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Schizophrenia - Companies Involved in Therapeutics Development:

AbbVie Inc., Acadia Pharmaceuticals Inc., Adamed Sp. z o.o., Addex Therapeutics Ltd, Aestus Therapeutics, Inc., AGY Therapeutics, Inc., Alkermes Plc, Amgen Inc., Angita B.V., Ascendis Pharma A/S, Astellas Pharma Inc., Athersys, Inc., BioCrea GmbH, Biotie Therapies Corp., Boehringer Ingelheim GmbH, BRAINco Biopharma, S.L., Cerecor Inc., Critical Pharmaceuticals Limited, Curemark, LLC, Delpor, Inc., Domain Therapeutics SA, Dong Wha Pharma Co., Ltd., Echo Pharmaceuticals B.V., Egis Gyogyszergyar Nyrt, Eli Lilly and Company, Evotec AG, F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., Galenea Corp., GeNeuro SA, Genovate Biotechnology Co., LTD., Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., GP Pharm, S.A., GW Pharmaceuticals plc, H. Lundbeck A/S, Heptares Therapeutics Ltd., Hisamitsu Pharmaceutical Co., Inc., Intra-Cellular Therapies, Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiangsu Nhwa Pharma Corporation, Johnson & Johnson, Karuna Pharmaceuticals Inc., KemPharm, Inc., Laboratorios Farmaceuticos Rovi, S.A., Lead Discovery Center GmbH, Luye Pharma Group Ltd., MarcoPolo Pharmaceuticals SA, Merck & Co., Inc., Mithridion, Inc., Mitsubishi Tanabe Pharma Corporation, Naurex, Inc., Neurocrine Biosciences, Inc., NeurOp, Inc, Newron Pharmaceuticals S.p.A., Novartis AG, Nuvo Research Inc., Omeros Corporation, Otsuka Holdings Co., Ltd, Peptron, Inc., Pfizer Inc., Promentis Pharmaceuticals, Inc., Reckitt Benckiser Pharmaceutical, Inc., Reviva Pharmaceuticals Inc, Richter Gedeon Nyrt., Rottapharm SpA, SK Biopharmaceuticals Co., Ltd., SK Chemicals Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd, Sunovion Pharmaceuticals Inc., Suven Life Sciences Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Targacept, Inc., Tetra Discovery Partners LLC, Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., XTL Biopharmaceuticals Ltd., Zogenix, Inc., Zysis Limited.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=235901

Scope:

-The report provides a snapshot of the global therapeutic landscape of Schizophrenia

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Reasons to buy:

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Develop strategic initiatives by understanding the focus areas of leading companies

-Identify and understand important and diverse types of therapeutics under development for Schizophrenia

-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

-Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Neurology therapeutics Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Chronic Kidney Disease (Chronic Renal Failure)’s therapeutic pipeline.

Dallas, TX -- (SBWIRE) -- 10/30/2014 -- This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects.

Chronic kidney disease is identified by a blood test for creatinine. Higher levels of creatinine indicate a lower glomerular filtration rate and as a result a decreased capability of the kidneys to excrete waste products. Creatinine levels may be normal in the early stages of CKD, and the condition is discovered if urinalysis (testing of a urine sample) shows that the kidney is allowing the loss of protein or red blood cells into the urine. To fully investigate the underlying cause of kidney damage, various forms of medical imaging, blood tests and often renal biopsy (removing a small sample of kidney tissue) are employed to find out if there is a reversible cause for the kidney malfunction. Recent professional guidelines classify the severity of chronic kidney disease in five stages, with stage 1 being the mildest and usually causing few symptoms and stage 5 being a severe illness with poor life expectancy if untreated. Stage 5 CKD is often called end stage renal disease (ESRD), end stage renal failure (ESRF), or end-stage kidney disease (ESKD) and is synonymous with the now outdated terms chronic kidney failure (CKF) or chronic renal failure (CRF).

Complete Report Available @ http://www.rnrmarketresearch.com/chronic-kidney-disease-chronic-renal-failure-pipeline-review-h2-2014-market-report.html.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development:

Hospira, Inc.; AstraZeneca PLC; Eli Lilly and Company; Quark Pharmaceuticals, Inc.; Astellas Pharma Inc.; OPKO Health, Inc.; Toray Industries, Inc.; Evotec AG; NPS Pharmaceuticals, Inc; La Jolla Pharmaceutical Company; Alexion Pharmaceuticals, Inc.; AFFiRiS AG; Acceleron Pharma, Inc.; Nippon Zoki; Pharmaceutical Co., Ltd.; Catabasis Pharmaceuticals, Inc.; Angion Biomedica Corp.; Concert Pharmaceuticals, Inc.; Intercept Pharmaceuticals, Inc.; Vitae Pharmaceuticals, Inc.; TRACON Pharmaceuticals, Inc.; Stelic Institute & Co.; Vicore Pharma AB; Otsuka Holdings Co., Ltd.; Sphaera Pharma Pvt. Ltd.; Multi Gene Vascular Systems Ltd; Bio-inRen; Red Glead Discovery AB.

Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235035 .

Chronic Kidney Disease (Chronic Renal Failure) Drug Profiles:

beraprost sodium LA, cinacalcet hydrochloride, epoetin zeta, sotatercept, eculizumab, GCS-100, tolvaptan, tenapanor hydrochloride, LY-3016859, SP-20103, VTP-27999, CTP-499, LY-3113593, Peptide to Modulate GHSR for Chronic Kidney Disease, KBP-5074, INT-767, C-21, CAT-4000 Series, ANG-3070, MultiGeneGraft, CXA-10, CAT-4001, SphK2 Program, (docetaxel + ceramide), AS-2444697, NZ-419, Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease, Vida-5, Vaccine for Chronic Kidney Disease, Small Molecules for Chronic Kidney Disease, siRNA for Chronic Diseases, STNM-310, Drug for Kidney Diseases, Small Molecules for Chronic Kidney Disease, Drugs to Inhibit CYP24 for CKD and Pre-CKD, Small Molecules for Chronic Kidney Disease, Fluorophosphophloretin, BRN-1889, ANG-3557.

Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Renal therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/kidney/kidneyrenal-therapeutics.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Dengue – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Dengue’s therapeutic pipeline.

Dallas, TX -- (SBWIRE) -- 10/29/2014 -- This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

Dengue fever also known as breakbone fever, is a mosquito-borne tropical disease caused by the dengue virus. Symptoms include fever, headache, muscle and joint pains, and a characteristic skin rash that is similar to measles. In a small proportion of cases the disease develops into the life-threatening dengue hemorrhagic fever, resulting in bleeding, low levels of blood platelets and blood plasma leakage, or into dengue shock syndrome, where dangerously low blood pressure occurs.

Complete Report Available @ http://www.rnrmarketresearch.com/dengue-pipeline-review-h2-2014-market-report.html.

Dengue is transmitted by several species of mosquito within the genus Aedes, principally A. aegypti. The virus has five different types; infection with one type usually gives lifelong immunity to that type, but only short-term immunity to the others. Subsequent infection with a different type increases the risk of severe complications. As there is no commercially available vaccine, prevention is sought by reducing the habitat and the number of mosquitoes and limiting exposure to bites.

Dengue - Companies Involved in Therapeutics Development:

United Therapeutics Corporation; GlaxoSmithKline plc; Merck & Co., Inc.; Takeda Pharmaceutical Company Limited; FIT Biotech Oyj; Biological E. Limited; Biotron Limited; Sarepta Therapeutics, Inc.; Medivir AB; BioDiem Ltd; NanoViricides, Inc.; SIGA Technologies, Inc. (Inactive); Panacea Biotec Limited; Bharat Biotech International Limited; TechnoVax, Inc.; MacroGenics, Inc.; PTC Therapeutics, Inc.; Kineta, Inc.; Immunovaccine, Inc.; VaxInnate Corporation; Janssen Pharmaceuticals, Inc.; Cocrystal Pharma, Inc.
PaxVax; RFS Pharma, LLC; AltraVax Inc.; Visterra, Inc.; Arbovax, Inc.; Sanofi Pasteur SA; Themis Bioscience GmbH; Agilvax, Inc.; Humabs BioMed SA; Codagenix, Inc.

Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235019.

Dengue Drug Profiles:
dengue vaccine [types 1,2,3,4] (tetravalent); TAK-003; dengue vaccine 3; dengue vaccine {rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30 }(tetravalent); celgosivir hydrochloride; dengue vaccine 4; V-180; DNA Vaccine for Dengue; DENV-1 PIV; UV-4B; modipafant; ST-148; DengueCide; TVX-005; dengue vaccine (DEN-2); AVI-6006; dengue vaccine; DV-2-G460P; ST-610; rOAS; dengue vaccine (tetravalent); GREDEN/V1-4; VIS-513

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope
- The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Therapeutics Drugs Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Multiple Sclerosis – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Multiple Sclerosis’s therapeutic pipeline.

Dallas, TX -- (SBWIRE) -- 10/29/2014 -- "This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often occur, especially as the disease advances.

Complete Report Available
http://www.rnrmarketresearch.com/multiple-sclerosis-pipeline-review-h2-2014-market-report.html .

Multiple Sclerosis - Companies Involved in Therapeutics Development:

Genzyme Corporation; Biogen Idec Inc.; Advanced Cell Technology, Inc.; Athersys, Inc.; GlaxoSmithKline plc; Inovio Pharmaceuticals, Inc. ; MedImmune, LLC; Biotest AG; Alkermes Plc; Plexxikon Inc.; Apitope International NV; Hanwha Chemical Co., Ltd.; Aphios Corporation; Acorda Therapeutics, Inc.; Biocon Limited; Eisai Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; Ono Pharmaceutical Co., Ltd.; Pfizer Inc.; Rigel Pharmaceuticals, Inc.; Vertex Pharmaceuticals Incorporated; Zydus Cadila Healthcare Limited; Paratek Pharmaceuticals, Inc.; OPKO Health, Inc.; BrainStorm Cell Therapeutics Inc.; Merck KGaA

4SC AG; Addex Therapeutics Ltd; Evotec AG; Harbor Therapeutics, Inc.; Neuralstem, Inc.; Idera Pharmaceuticals, Inc.; Karo Bio AB; Almirall, S.A.; Lpath, Inc.; Bionomics Limited; MultiCell Technologies, Inc.; Neuren Pharmaceuticals Limited; Catalyst Pharmaceutical Partners, Inc.; Compugen Ltd.; Critical Outcome Technologies Inc.; Acadia Pharmaceuticals Inc. ;RegeneRx Biopharmaceuticals, Inc.; NeoStem, Inc.; Array BioPharma Inc. ; Xenetic Biosciences plc; HanAll Biopharma Co., Ltd; LG Life Sciences, Ltd.; Pluristem Therapeutics Inc.; Resverlogix Corp. ; Sareum Holdings plc; InDex Pharmaceuticals AB; Morphotek, Inc.; Digna Biotech, S.L.; Antipodean Pharmaceuticals, Inc.; Antitope Ltd.; Axxam SpA

Pieris AG; Hutchison MediPharma Limited; Argos Therapeutics, Inc.; Affectis Pharmaceuticals AG; Coronado Biosciences, Inc.; MacroGenics, Inc.; Q Therapeutics, Inc.; Catabasis Pharmaceuticals, Inc.; Vaccinex, Inc.; Kineta, Inc.; MSM Protein Technologies, Inc.; Vascular Biogenics Ltd.; Endocyte, Inc.; Theraclone Sciences, Inc.; Effimune SAS; InteKrin Therapeutics, Inc.; Siena Biotech S.p.A.; Virogenomics, Inc.; Omeros Corporation; Bolder Biotechnology, Inc.; Aegis Therapeutics, LLC; Dimerix Bioscience Pty Ltd; Cellceutix Corporation; Biovista Inc.; Invion Limited; SanBio, Inc.; KaloBios Pharmaceuticals, Inc.; Provid Pharmaceuticals, Inc.; Vitae Pharmaceuticals, Inc.; Biokine Therapeutics Ltd.; OncoImmune, Inc.

to-BBB technologies BV; KAHR medical Ltd.; Lycera Corp.; MAKScientific, LLC; RhinoCyte, Inc.; Vakzine Projekt Management GmbH; KAEL-GemVax Co., Ltd.; Pfenex Inc.; Vicore Pharma AB; Cellmid Limited; Synthon BV; Varinel, Inc.; Cognosci, Inc.; Immune Technologies and Medicine; Targazyme, Inc.; ProNoxis AB; Cell Cure Neurosciences, Ltd.; GeNeuro SA; VivaCell Biotechnology Espana S.L; Forward Pharma A/S; Genervon Biopharmaceuticals, LLC; Regenesance BV; Inbiopro Solutions Pvt. Ltd.; Kareus Therapeutics, SA; Lead Discovery Center GmbH; BRAINco Biopharma, S.L; Immunaffect B.V.; SOM Biotech SL; Immune Response BioPharma, Inc.; Bionure Farma, S.L.; IntelliCell BioSciences Inc.; The International Biotechnology Center (IBC) "Generium"; Arrien Pharmaceuticals, LLC; Creabilis SA; CalAsia

Pharmaceuticals, Inc.; Evgen Limited; SK Biopharmaceuticals Co., Ltd.; Io Therapeutics, Inc.; Lanthio; harma B.V.; ReveraGen BioPharma, Inc.; Ossianix, Inc.; Endece, LLC; Biomar Microbial Technologies

GliaCure Inc. ; ImmuNext, Inc.; Toleranzia AB; Mapi Pharma Ltd.; Regeneks; Glialogix, Inc.; Bionature E.A. Ltd.; Dong-A Socio Group.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=235011

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope:

-The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Reasons to buy:

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Develop strategic initiatives by understanding the focus areas of leading companies

-Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

-Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Multiple Sclerosis Drugs Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/multiple-sclerosis-drugs

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “China Negative Pressure Wound Therapy (NPWT) Market Outlook to 2020” report to its research database. The data in the report is derived from dynamic market forecast models.

Dallas, TX -- (SBWIRE) -- 10/27/2014 -- "China Negative Pressure Wound Therapy (NPWT) Market Outlook to 2020?, provides key market data on the China Negative Pressure Wound Therapy market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments – NPWT Rental Business and NPWT Sales Business (Stand Alone NPWT Devices, Portable NPWT Devices and NPWT Accessories).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Negative Pressure Wound Therapy market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Complete Report Available @ http://www.rnrmarketresearch.com/china-negative-pressure-wound-therapy-npwt-market-outlook-to-2020-market-report.html.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=233875 .

Scope
- Market size data for Negative Pressure Wound Therapy market segments NPWT Rental Business and NPWT Sales Business.
- Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.
- 2013 company shares and distribution shares data for Negative Pressure Wound Therapy market.
- Global corporate-level profiles of key companies operating within the China Negative Pressure Wound Therapy.
- Key players covered include Kinetic Concepts, Inc., WuHan VSD Medical Science & Technology Co., Ltd. and Shandong Wego Newlife Medical Device Co., Ltd.

Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=233875 . (This is a premium report priced at US$2500 for a single user License.)

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 What Is This Report About? 4
2.2 Negative Pressure Wound Therapy (NPWT) Market Segmentation 4
2.3 Definitions of Markets Covered in the Report 5

3 Negative Pressure Wound Therapy (NPWT) Market, China 6
3.1 Negative Pressure Wound Therapy (NPWT) Market, China, Revenue ($m), 2005-2013 6
3.2 Negative Pressure Wound Therapy (NPWT) Market, China, Revenue ($m), 2013-2020 8
3.2.1 NPWT Sales Business Market, China, Revenue ($m), by Segment, 2005-2013 10
3.2.2 NPWT Sales Business Market, China, Revenue ($m), by Segment, 2013-2020 12
3.3 Negative Pressure Wound Therapy (NPWT) Market, China, Volume (Units), 2005-2013 14
3.4 Negative Pressure Wound Therapy (NPWT) Market, China, Volume (Units), 2013-2020 15
3.4.1 NPWT Sales Business Market, China, Volume (Units), by Segment, 2005-2013 16
3.4.2 NPWT Sales Business Market, China, Volume (Units), by Segment, 2013-2020 18
3.5 Negative Pressure Wound Therapy (NPWT) Market, China, Average Price ($), 2005-2020 20
3.6 Negative Pressure Wound Therapy (NPWT) Market, China, Distribution Share by Revenue ($m), 2012-2013 21
3.7 Negative Pressure Wound Therapy (NPWT) Market, China, Company Share by Revenue ($m), 2012-2013 22

4 Overview of Key Companies in China, Negative Pressure Wound Therapy (NPWT) Market 23
4.1 WuHan VSD Medical Science & Technology Co., Ltd. 23
4.1.1 Company Overview 23
4.2 Shandong Wego Newlife Medical Device Co., Ltd. 23
4.2.1 Company Overview 23
4.3 Kinetic Concepts, Inc. 23
4.3.1 Company Overview 23
4.4 Smith & Nephew Plc 23
4.4.1 Company Overview 23

5 Negative Pressure Wound Therapy (NPWT) Market Pipeline Products 24

6 Appendix 25
6.1 Research Methodology 26
6.1.1 Coverage 26
6.1.2 Secondary Research 26
6.1.3 Primary Research 27
6.1.4 Market Modeling and Forecasting 28
6.1.5 Company Share Analysis 31
6.1.6 Distribution Share Analysis 32
6.2 Expert Panel 32
6.3 GlobalData Consulting 33
6.4 Contact Us 33
6.5 Disclaimer 33

Browse more reports on Medical Devices Market @ http://www.rnrmarketresearch.com/reports/life-sciences/medical-devices .

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Dallas, TX -- (SBWIRE) -- 10/22/2014 -- RnRMarketResearch.com adds "United States Ostomy Drainage Bags Market Outlook to 2020" report to its research database. The data in the report is derived from dynamic market forecast models.

"United States Ostomy Drainage Bags Market Outlook to 2020?, provides key market data on the United States Ostomy Drainage Bags market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments Colostomy (One Piece Colostomy Drainage Bags (Closed and Drainable One Piece Colostomy Drainage Bags) and Two Piece Colostomy Drainage Bags (Closed and Drainable Two Piece Colostomy Drainage Bags)), Ileostomy (One Piece Ileostomy Drainage Bags (Closed and Drainable One Piece Ileostomy Drainage Bags) and Two Piece Ileostomy Drainage Bags (Closed and Drainable Two Piece Ileostomy Drainage Bags)) and Urostomy (One Piece Urostomy Drainage Bags (Closed and Drainable One Piece Urostomy Drainage Bags) and Two Piece Urostomy Drainage Bags (Closed and Drainable Two Piece Urostomy Drainage Bags)).

Complete Report Available
http://www.rnrmarketresearch.com/united-states-ostomy-drainage-bags-market-outlook-to-2020-market-report.html

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Ostomy Drainage Bags market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=232650

Overview of Key Companies in United States, Ostomy Drainage Bags Market:

-Hollister Incorporated
-Coloplast A/S
-Alcare Co., Ltd.
-B. Braun Melsungen AG
-ConvaTec Inc.
-Nu-Hope Laboratories, Inc.

Scope:

-Market size data for Ostomy Drainage Bags market segments Colostomy, Ileostomy and Urostomy.

-Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.

-2013 company shares and distribution shares data for Ostomy Drainage Bags market.

-Global corporate-level profiles of key companies operating within the United States Ostomy Drainage Bags.

-Key players covered include ConvaTec Inc., Hollister Incorporated and Coloplast A/S.

Reasons to buy:

-Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.

-Develop market-entry and market expansion strategies.

-Design competition strategies by identifying who-stands-where in the market.

-Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

-What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 What Is This Report About?
2.2 Ostomy Drainage Bags Market Segmentation
2.3 Definitions of Markets Covered in the Report

3 Ostomy Drainage Bags Market, United States
3.1 Ostomy Drainage Bags Market, United States, Revenue ($m), 2005-2013
3.2 Ostomy Drainage Bags Market, United States, Revenue ($m), 2013-2020
3.3 Ostomy Drainage Bags Market, United States, Volume (Units), 2005-2013
3.4 Ostomy Drainage Bags Market, United States, Volume (Units), 2013-2020
3.5 Ostomy Drainage Bags Market, United States, Average Price ($), 2005-2020
3.6 Ostomy Drainage Bags Market, United States, Distribution Share by Revenue ($m), 2012-2013
3.7 Ostomy Drainage Bags Market, United States, Company Share by Revenue ($m), 2012-2013

4 Overview of Key Companies in United States, Ostomy Drainage Bags Market

5 Financial Deals Landscape
5.1 Acquisition
5.2 Debt Offerings
5.3 Partnerships

6 Recent Developments
6.1 Corporate Communications
6.2 Financial Announcements
6.3 Product News
6.4 Strategy And Business Planning

7 Appendix 106

Browse more reports on Medical Devices Market
http://www.rnrmarketresearch.com/reports/life-sciences/medical-devices

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “United States Advanced Wound Management Market Outlook to 2020” report to its research database. The data in the report is derived from dynamic market forecast models.

Dallas, TX -- (SBWIRE) -- 10/22/2014 -- "United States Advanced Wound Management Market Outlook to 2020, provides key market data on the United States Advanced Wound Management market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments Semi-Permeable Films (Antimicrobial Film Dressings (Antimicrobial Bordered and Non Bordered Film Dressings) and Non Antimicrobial Film Dressings (Non Antimicrobial Bordered and Non Bordered Film Dressings)), Foams (Antimicrobial Foam Dressings (Antimicrobial Bordered and Non Bordered Foam Dressings) and Non Antimicrobial Foam Dressings (Non Antimicrobial Bordered and Non Bordered Foam Dressings)), Hydrofibres (Antimicrobial and Non Antimicrobial Hydrofibre Dressings), Hydrocolloids (Antimicrobial and Non Antimicrobial Hydrocolloid Dressings), Hydrogels (Antimicrobial and Non Antimicrobial Hydrogel Dressings), Alginates (Antimicrobial and Non Antimicrobial Alginate Dressings), Collagens (Antimicrobial and Non Antimicrobial Collagen Dressings), Wound Contact Layers (Antimicrobial and Non Antimicrobial Wound Contact Layers) and Superabsorbents (Antimicrobial and Non Antimicrobial Superabsorbents).

Complete Report Available @ http://www.rnrmarketresearch.com/united-states-advanced-wound-management-market-outlook-to-2020-market-report.html .

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Advanced Wound Management market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=232646 .

Overview of Key Companies in United States, Advanced Wound Management Market:
- 3M Health Care Ltd
- Smith & Nephew Plc
- Medline Industries, Inc.
- Molnlycke Health Care AB
- Coloplast A/S
- Systagenix Wound Management Limited
- Covidien plc
- BSN medical GmbH
- Derma Sciences, Inc.
- Paul Hartmann AG
- Hollister Incorporated
- Laboratoires Urgo S.A.
- ConvaTec Inc.

Scope
- Market size data for Advanced Wound Management market segments Semi-Permeable Films, Foams, Hydrofibres, Hydrocolloids, Hydrogels, Alginates, Collagens, Wound Contact Layers and Superabsorbents.
- Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.
- 2013 company shares and distribution shares data for Advanced Wound Management market.
- Global corporate-level profiles of key companies operating within the United States Advanced Wound Management market.
- Key players covered include 3M Health Care Ltd., Smith & Nephew Plc and ConvaTec Inc.

Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 What Is This Report About?
2.2 Advanced Wound Management Market Segmentation
2.3 Definitions of Markets Covered in the Report

3 Advanced Wound Management Market, United States
3.1 Advanced Wound Management Market, United States, Revenue ($m), 2005-2013
3.2 Advanced Wound Management Market, United States, Revenue ($m), 2013-2020
3.3 Advanced Wound Management Market, United States, Volume (Units), 2005-2013
3.4 Advanced Wound Management Market, United States, Volume (Units), 2013-2020
3.5 Advanced Wound Management Market, United States, Average Price ($), 2005-2020
3.6 Advanced Wound Management Market, United States, Distribution Share by Revenue ($m), 2012-2013
3.7 Advanced Wound Management Market, United States, Company Share by Revenue ($m), 2012-2013

4 Overview of Key Companies in United States, Advanced Wound Management Market

5 Advanced Wound Management Market Pipeline Products

6 Financial Deals Landscape
6.1 Acquisition
6.2 Equity Offerings
6.3 Partnerships
6.4 Private Equity
6.5 Venture Financing

7 Recent Developments
7.1 Corporate Communications
7.2 Financial Announcements
7.3 Government and Public Interest
7.4 Legal And Regulatory
7.5 Other Significant Developments
7.6 Product News
7.7 Strategy And Business Planning

8 Appendix

Browse more reports on Wound Care device Market @ http://www.rnrmarketresearch.com/reports/life-sciences/medical-devices/wound-care-device .

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Japan Negative Pressure Wound Therapy (NPWT) Market Outlook to 2020” report to its research database. The data in the report is derived from dynamic market forecast models.

Dallas, TX -- (SBWIRE) -- 10/21/2014 -- "Japan Negative Pressure Wound Therapy (NPWT) Market Outlook to 2020?, provides key market data on the Japan Negative Pressure Wound Therapy market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments NPWT Rental Business and NPWT Sales Business (Stand Alone NPWT Devices, Portable NPWT Devices, NPWT Accessories and NPWT Disposable Devices).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Negative Pressure Wound Therapy market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Complete Report Available
http://www.rnrmarketresearch.com/japan-negative-pressure-wound-therapy-npwt-market-outlook-to-2020-market-report.html

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=232684

Overview of Key Companies in Japan, Negative Pressure Wound Therapy (NPWT) Market:

-Kinetic Concepts, Inc.
-Smith & Nephew Plc
-Shandong Wego Newlife Medical Device Co., Ltd.

Scope:

-Market size data for Negative Pressure Wound Therapy market segments NPWT Rental Business and NPWT Sales Business.

-Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.

-2013 company shares and distribution shares data for Negative Pressure Wound Therapy market.

-Global corporate-level profiles of key companies operating within the Japan Negative Pressure Wound Therapy.

-Key players covered include Kinetic Concepts, Inc. and Smith & Nephew Plc.

Reasons to buy:

-Develop business strategies by identifying the key market categories and segments poised for strong growth in the future

-Develop market-entry and market expansion strategies.

-Design competition strategies by identifying who-stands-where in the market.

-Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

-What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 What Is This Report About? 4
2.2 Negative Pressure Wound Therapy (NPWT) Market Segmentation 4
2.3 Definitions of Markets Covered in the Report 5
3 Negative Pressure Wound Therapy (NPWT) Market, Japan 6
3.1 Negative Pressure Wound Therapy (NPWT) Market, Japan, Revenue ($m), 2005-2013 6
3.2 Negative Pressure Wound Therapy (NPWT) Market, Japan, Revenue ($m), 2013-2020 8
3.2.1 NPWT Sales Business Market, Japan, Revenue ($m), by Segment, 2005-2013 10
3.2.2 NPWT Sales Business Market, Japan, Revenue ($m), by Segment, 2013-2020 12
3.3 Negative Pressure Wound Therapy (NPWT) Market, Japan, Volume (Units), 2005-2013 14
3.4 Negative Pressure Wound Therapy (NPWT) Market, Japan, Volume (Units), 2013-2020 15
3.4.1 NPWT Sales Business Market, Japan, Volume (Units), by Segment, 2005-2013 16
3.4.2 NPWT Sales Business Market, Japan, Volume (Units), by Segment, 2013-2020 18
3.5 Negative Pressure Wound Therapy (NPWT) Market, Japan, Average Price ($), 2005-2020 20
3.6 Negative Pressure Wound Therapy (NPWT) Market, Japan, Distribution Share by Revenue ($m), 2012-2013 22
3.7 Negative Pressure Wound Therapy (NPWT) Market, Japan, Company Share by Revenue ($m), 2012-2013 23
4 Overview of Key Companies in Japan, Negative Pressure Wound Therapy (NPWT) Market 25
4.1 Kinetic Concepts, Inc. 25
4.1.1 Company Overview 25
4.2 Smith & Nephew Plc 25
4.2.1 Company Overview 25
4.3 Shandong Wego Newlife Medical Device Co., Ltd. 25
4.3.1 Company Overview 25
5 Negative Pressure Wound Therapy (NPWT) Market Pipeline Products 26

6 Appendix 27
6.1 Research Methodology 28
6.1.1 Coverage 28
6.1.2 Secondary Research 28
6.1.3 Primary Research 29
6.1.4 Market Modeling and Forecasting 30
6.1.5 Company Share Analysis 33
6.1.6 Distribution Share Analysis 34
6.2 Expert Panel 34
6.3 GlobalData Consulting 35
6.4 Contact Us 35
6.5 Disclaimer 35

Browse more reports on Wound Care device Market
http://www.rnrmarketresearch.com/reports/life-sciences/medical-devices/wound-care-device

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Insulin Resistance – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Insulin Resistance’s therapeutic pipeline.

Dallas, TX -- (SBWIRE) -- 10/17/2014 -- This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.

Insulin resistance (IR) is a physiological condition in which cells fail to respond to the normal actions of the hormone insulin. The body produces insulin, but the cells in the body become resistant to insulin and are unable to use it as effectively, leading to hyperglycemia. Beta cells in the pancreas subsequently increase their production of insulin, further contributing to hyperinsulinemia. This often remains undetected and can contribute to a diagnosis of Type 2 Diabetes or latent autoimmune diabetes of adults.

Complete Report Available
http://www.rnrmarketresearch.com/insulin-resistance-pipeline-review-h2-2014-market-report.html

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=231435

Insulin Resistance - Companies Involved in Therapeutics Development:

-Sanofi
-GlaxoSmithKline plc
-Mochida Pharmaceutical Co., Ltd.
-Novartis AG
-Hadasit Medical Research Services & Development Ltd
-Genfit SA
-N-Gene Research Laboratories, Inc.
-AUS Bio Limited
-Thetis Pharmaceuticals LLC

Insulin Resistance - Drug Profiles:

GFT-505, BGP-15, BVS-857, Protein Kinase C Derived Peptides, MD-960, Drug to Activate AMPK Beta for Inflammation and Insulin Resistance, Small Molecule to Antagonize TRPV4, Drugs to Inhibit TRIP-Br2 for Metabolic Disorders, Small Molecule Targeting AMPD2 for Hypertension and Metabolic Disorders, Small Molecules to Inhibit DGAT-1 for Metabolic Disorders, Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular, Peptide for Obesity and Insulin Resistance, Englerin A, Small Molecule for Atherosclerosis and Insulin Resistance, Antisense Oligonucleotides Targeting ABHD6 for Gastrointestinal and Metabolic Disorders, SAR-088, Small Molecule for Hypertension and Insulin Resistance, TP-113, SERX-1, Small Molecules to Inhibit PARP for Immunology Oncology Cardiovascular and Metabolic Disorders, Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders.

Scope:

- The report provides a snapshot of the global therapeutic landscape of Insulin Resistance

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Inquire for Discount
http://www.rnrmarketresearch.com/contacts/discount?rname=231435
(This is a premium report priced at US$2000 for a single user License.)

Reasons to buy:

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Insulin Resistance

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Diabetes Therapeutics Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/diabetes-therapeutics

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Cardiomyopathy – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Cardiomyopathy’s therapeutic pipeline.

Dallas, TX -- (SBWIRE) -- 10/17/2014 -- This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects.

Cardiomyopathy (literally "heart muscle disease") is the measurable deterioration for any reason of the ability of the myocardium (the heart muscle) to contract, usually leading to heart failure. Common symptoms include dyspnea (breathlessness) and peripheral edema (swelling of the legs). Those with cardiomyopathy are often at risk of dangerous forms of irregular heart rate and sudden cardiac death.

Complete Report Available
http://www.rnrmarketresearch.com/cardiomyopathy-pipeline-review-h2-2014-market-report.html

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=231465

Scope:

-The report provides a snapshot of the global therapeutic landscape of Cardiomyopathy

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Cardiomyopathy and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Inquire for Discount
http://www.rnrmarketresearch.com/contacts/discount?rname=231465
(This is a premium report priced at US$2000 for a single user License.)

Reasons to buy:

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Develop strategic initiatives by understanding the focus areas of leading companies

-Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy

-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

-Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Cardiovascular therapeutics Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cardiovascular-therapeutics

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Polycystic Ovarian Syndrome – Pipeline Review, H2 2014” report to its research database. This report provides an overview of the Polycystic Ovarian Syndrome’s therapeutic pipeline.

Dallas, TX -- (SBWIRE) -- 10/15/2014 -- This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects.

Polycystic ovary syndrome (PCOS), also called hyperandrogenic anovulation (HA), or Stein-Leventhal syndrome, is one of the most common endocrine disorders among females. PCOS has a diverse range of causes that are not entirely understood, but there is evidence that it is largely a genetic disease. Others say it is generally a metabolic dysfunction, since it is reversible. Even though considered as a gynecological problem, PCOS is comprised of 28 clinical symptoms.

Even though the name suggest that the ovaries are the cornerstone of disease pathology, cysts are the 'result' , not the cause of the disease. Symptoms of PCOS will persist even if both ovaries are removed, the disease can appear even if cysts are absent. Since it's first description by Stein and Leventhal in 1935, the criteria of diagnosis, symptoms, and causative factors are subject to debate. Gynecologists often see it as a gynaecological problem, with ovary as the primary organ affected. However, recent insights shows a multisystem disorder, with the primary problems lies in hormonal regulation in hypothalamus, with involvement of many organs. The name PCOD is used when there is an ultrasonographic evidence. The term PCOS is used since there is a wide spectrum of symptoms possible, and cysts in the ovaries are seen only in 15% of people. Treatments like wedge resection or laparoscopic drilling of ovaries are still performed around the world, based on this false 'ovary- focused' belief.

Complete Report Available
http://www.rnrmarketresearch.com/polycystic-ovarian-syndrome-pipeline-review-h2-2014-market-report.html

PCOS produces symptoms in approximately 5% to 10% of women of reproductive age (approximately 12 to 45 years old). It is thought to be one of the leading causes of female subfertility and the most frequent endocrine problem in women of reproductive age. Finding that the ovaries appear polycystic on ultrasound is common, but it is not an absolute requirement in all definitions of the disorder.

The most common immediate symptoms are anovulation, excess androgenic hormones, and insulin resistance. Anovulation results in irregular menstruation, amenorrhea, and ovulation-related infertility. Hormone imbalance generally causes acne and hirsutism. Insulin resistance is associated with obesity, type 2 diabetes, and high cholesterol levels. The symptoms and severity of the syndrome vary greatly among affected women.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=213395

Scope:

-The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Reasons to buy:

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Develop strategic initiatives by understanding the focus areas of leading companies

-Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome

-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

-Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Women's Health therapeutics Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Chronic Heart Failure Global Clinical Trials Review & Pipeline Review, H2, 2014” report to its research database. This report provides an overview of the Chronic Heart Failure’s therapeutic pipeline & Clinical Trials.

Dallas, TX -- (SBWIRE) -- 10/14/2014 -- Heart failure (HF), often used to mean chronic heart failure (CHF), occurs when the heart is unable to pump sufficiently to maintain blood flow to meet the needs of the body. The terms congestive heart failure (CHF) or congestive cardiac failure (CCF) are often used interchangeably with chronic heart failure. Symptoms commonly include shortness of breath, excessive tiredness, and leg swelling. The shortness of breath is usually worse with exercise, when lying down, and at night while sleeping. There is often a limitation on the amount of exercise people can perform, even when well treated.

Chronic Heart Failure Global Clinical Trials Review, H2, 2014

"Chronic Heart Failure Global Clinical Trials Review, H2, 2014? provides data on the Chronic Heart Failure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Heart Failure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Heart Failure.

Complete Report on Chronic Heart Failure Global Clinical Trials Review, H2, 2014 Details @ http://www.rnrmarketresearch.com/chronic-heart-failure-global-clinical-trials-review-h2-2014-market-report.html . OR Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=210356.

Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Chronic Heart Failure – Pipeline Review, H2 2014

This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Complete Report on Chronic Heart Failure – Pipeline Review, H2 2014 @ http://www.rnrmarketresearch.com/chronic-heart-failure-pipeline-review-h2-2014-market-report.html . OR Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=197313 .

Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Pharmaceuticals Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RnRMarketResearch.com adds “Behcet’s Disease Global Clinical Trials Review, H2, 2014” report to its research database. This report provides elemental information and data relating to the clinical trials on Behcet’s Disease.

Dallas, TX -- (SBWIRE) -- 10/13/2014 -- Clinical trial report, "Behcet's Disease Global Clinical Trials Review, H2, 2014? provides data on the Behcet's Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Behcet's Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Behcet's Disease.

Behcet's disease or Behcet disease sometimes called Behcet's syndrome, Morbus Behcet, Behcet-Adamantiades syndrome, or Silk Road disease, is a rare immune-mediated small-vessel systemic vasculitis that often presents with mucous membrane ulceration and ocular problems. Behcet's disease (BD) was named in 1937 after the Turkish dermatologist Hulusi Behcet, who first described the triple-symptom complex of recurrent oral aphthous ulcers, genital ulcers, and uveitis. As a systemic disease, it can also involve visceral organs such as the gastrointestinal tract, pulmonary, musculoskeletal, cardiovascular and neurological systems. This syndrome can be fatal due to ruptured vascular aneurysms or severe neurological complications.

Complete Report Details @ http://www.marketoptimizer.org/behcets-disease-global-clinical-trials-review-h2-2014.html .

Scope:

-Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations

-Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

-Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to Buy:

-Understand the dynamics of a particular indication in a condensed manner

-Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

-Obtain discontinued trial listing for trials across the globe

-Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=11435

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Behcet's Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Behcet's Disease to Immunology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Behcet's Disease to Immunology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Behcet's Disease 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Behcet's Disease Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
XOMA Corporation 32
Clinical Trial Overview of XOMA Corporation 32
AbbVie Inc. 33
Clinical Trial Overview of AbbVie Inc. 33
Novartis AG 34
Clinical Trial Overview of Novartis AG 34
Celgene Corporation 35
Clinical Trial Overview of Celgene Corporation 35
Nobelpharma Co., Ltd. 36
Clinical Trial Overview of Nobelpharma Co., Ltd. 36
Mitsubishi Chemical Holdings Corporation 37
Clinical Trial Overview of Mitsubishi Chemical Holdings Corporation 37
Les Laboratoires Servier SAS 38
Clinical Trial Overview of Les Laboratoires Servier SAS 38
Clinical Trial Overview of Top Institutes / Government 39
Tehran University of Medical Sciences 39
Clinical Trial Overview of Tehran University of Medical Sciences 39
National Institute of Arthritis and Musculoskeletal and Skin Diseases 40
Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases 40
New York University School of Medicine 41
Clinical Trial Overview of New York University School of Medicine 41
University Hospital Tubingen 42
Clinical Trial Overview of University Hospital Tubingen 42
National Eye Institute 43
Clinical Trial Overview of National Eye Institute 43
Cukurova University 44
Clinical Trial Overview of Cukurova University 44
Erasmus MC 45
Clinical Trial Overview of Erasmus MC 45
Rambam Health Care Campus 46
Clinical Trial Overview of Rambam Health Care Campus 46
Shiraz University of Medical Sciences 47
Clinical Trial Overview of Shiraz University of Medical Sciences 47
Asan Medical Center 48
Clinical Trial Overview of Asan Medical Center 48
Five Key Clinical Profiles 49
Appendix 77
Abbreviations 77
Definitions 77
Research Methodology 78
Secondary Research 78
About GlobalData 79
Contact Us 79
Disclaimer 79
Source 80

Browse more reports on Clinical Trial Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Dallas, TX -- (SBWIRE) -- 10/03/2014 -- MarketOptimizer.org adds "Hypertropic Cardiomyopathy Global Clinical Trials Review, H2, 2014" report to its research database.

New clinical trial report, "Hypertropic Cardiomyopathy Global Clinical Trials Review, H2, 2014? provides data on the Hypertropic Cardiomyopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypertropic Cardiomyopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hypertropic Cardiomyopathy.

Complete Report Details @ http://www.marketoptimizer.org/hypertropic-cardiomyopathy-global-clinical-trials-review-h2-2014.html .

Scope
Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy
Understand the dynamics of a particular indication in a condensed manner
Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
Obtain discontinued trial listing for trials across the globe
Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Order a Purchase copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10702 .

Table of Contents
Table of Contents 2
List of Tables3
List of Figures 4
Introduction 5
Hypertropic Cardiomyopathy 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Hypertropic Cardiomyopathy to Cardiovascular Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Unaccomplished Trials of Hypertropic Cardiomyopathy 20
Subjects Recruited Over a Period of Time 21
Clinical Trials by Sponsor Type 22
Prominent Sponsors 23
Top Companies Participating in Hypertropic Cardiomyopathy Therapeutics Clinical Trials 24
Prominent Drugs 25
Clinical Trial Profiles 26
Clinical Trial Overview of Top Companies 26
Gilead Sciences, Inc. 26
Clinical Trial Overview of Gilead Sciences, Inc. 26
Novartis AG 27
Clinical Trial Overview of Novartis AG 27
Heart Metabolics Ltd. 28
Clinical Trial Overview of Heart Metabolics Ltd. 28
A. Menarini Industrie Farmaceutiche Riunite Srl 29
Clinical Trial Overview of A. Menarini Industrie Farmaceutiche Riunite Srl 29
Clinical Trial Overview of Top Institutes / Government 30
National Heart, Lung, and Blood Institute 30
Clinical Trial Overview of National Heart, Lung, and Blood Institute 30
Johns Hopkins University 31
Clinical Trial Overview of Johns Hopkins University 31
University of Miami 32
Clinical Trial Overview of University of Miami 32
Brigham and Women's Hospital 33
Clinical Trial Overview of Brigham and Women's Hospital 33
Stanford University 34
Clinical Trial Overview of Stanford University 34
University of Calgary 35
Clinical Trial Overview of University of Calgary 35
Johann Wolfgang Goethe University Hospitals 36
Clinical Trial Overview of Johann Wolfgang Goethe University Hospitals 36
Massachusetts General Hospital 37
Clinical Trial Overview of Massachusetts General Hospital 37
Duke University 38
Clinical Trial Overview of Duke University 38
Assistance Publique – Hopitaux de Paris 39
Clinical Trial Overview of Assistance Publique – Hopitaux de Paris 39
Five Key Clinical Profiles 40
Appendix 56
Abbreviations 56
Definitions 56
Research Methodology 57
Secondary Research 57
About GlobalData 58
Contact Us 58
Disclaimer 58
Source 58

Browse more reports on Pharmaceuticals Market @ http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Marketoptimizer.org adds “BRIC Non-Vascular Stents Market Outlook to 2020” report to its research database.

Dallas, TX -- (SBWIRE) -- 09/24/2014 -- "BRIC Non-Vascular Stents Market Outlook to 2020, provides key market data on the BRIC Non-Vascular Stents market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments – Biliary Stents (Plastic Biliary Stents and Metal Biliary Stents (Metal Non-Covered Biliary Stents, Metal Partially Covered Biliary Stents and Metal Fully Covered Biliary Stents)), Gastrointestinal Stents (Fully Covered, Partially Covered and Non-Covered Gastrointestinal Stents), Airway Stents (Silicone Airway Stents and Metallic Airway Stents (Fully Covered and Uncovered Metallic Airway Stents) and Urinary Tract Stents ((Ureteral Stents (Metal, Polymer and Bioabsorbable Ureteral Stents), Prostate Stents (Metal, Polymer and Bioabsorbable Prostate Stents) and Urethral Stents (Metal, Polymer and Bioabsorbable Urethral Stents).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Non-Vascular Stents market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Complete Report Details
http://www.marketoptimizer.org/bric-non-vascular-stents-market-outlook-to-2020.html

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope:

-Market size data for Non-Vascular Stents market segments – Biliary Stents (Plastic Biliary Stents and Metal Biliary Stents (Metal Non-Covered Biliary Stents, Metal Partially Covered Biliary Stents and Metal Fully Covered Biliary Stents)), Gastrointestinal Stents (Fully Covered, Partially Covered and Non-Covered Gastrointestinal Stents), Airway Stents (Silicone Airway Stents and Metallic Airway Stents (Fully Covered and Uncovered Metallic Airway Stents) and Urinary Tract Stents ((Ureteral Stents (Metal, Polymer and Bioabsorbable Ureteral Stents), Prostate Stents (Metal, Polymer and Bioabsorbable Prostate Stents) and Urethral Stents (Metal, Polymer and Bioabsorbable Urethral Stents)).

-Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.

-2013 company shares and distribution shares data for Non-Vascular Stents market.

-Global corporate-level profiles of key companies operating within the Non-Vascular Stents market.

-Key players covered include Boston Scientific, Taewoong Medical, Merit Medical, Cook Medical, PNN Medical, Teleflex, Inc. and C.R. Bard.

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=10494

Reasons to buy:

-Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.

-Develop market-entry and market expansion strategies.

-Design competition strategies by identifying who-stands-where in the market.

-Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

-What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents
1 Table of Contents
1 Table of Contents 2

2 Introduction 17
2.1 What Is This Report About? 17
2.2 Non-Vascular Stents Market Segmentation 17
2.3 Definitions of Markets Covered in the Report 18

3 Non-Vascular Stents Market, BRIC 21
3.1 Non-Vascular Stents Market, BRIC, Revenue ($m), 2005-2020 21
3.2 Non-Vascular Stents Market, BRIC, Category Comparison by Revenue ($m), 2005-2020 23
3.3 Non-Vascular Stents Market, BRIC, Revenue ($m), 2005-2013 24
3.4 Non-Vascular Stents Market, BRIC, Revenue ($m), 2013-2020 26
3.5 Non-Vascular Stents Market, BRIC, Volume (Units), 2005-2020 28
3.6 Non-Vascular Stents Market, BRIC, Volume (Units), 2005-2013 29
3.7 Non-Vascular Stents Market, BRIC, Volume (Units), 2013-2020 31
3.8 Non-Vascular Stents Market, BRIC, Company Share by Revenue ($m), 2012-2013 33

4 Non-Vascular Stents Market, Brazil 35
4.1 Non-Vascular Stents Market, Brazil, Revenue ($m), 2005-2013 35
4.2 Non-Vascular Stents Market, Brazil, Revenue ($m), 2013-2020 37
4.2.1 Biliary Stents Market, Brazil, Revenue ($m), by Segment, 2005-2013 39
4.2.1.1 Metal Biliary Stents Market, Brazil, Revenue ($m), by Sub Segment, 2005-2013 41
4.2.2 Gastrointestinal Stents Market, Brazil, Revenue ($m), by Segment, 2005-2013 43
4.2.3 Airway Stents Market, Brazil, Revenue ($m), by Segment, 2005-2013 45
4.2.3.1 Metallic Airway Stents Market, Brazil, Revenue ($m), by Sub Segment, 2005-2013 46
4.2.4 Urinary Tract Stents Market, Brazil, Revenue ($m), by Segment, 2005-2013 47
4.2.4.1 Prostate Stents Market, Brazil, Revenue ($m), by Sub Segment, 2005-2013 49
4.2.4.2 Ureteral Stents Market, Brazil, Revenue ($m), by Sub Segment, 2005-2013 50
4.2.4.3 Urethral Stents Market, Brazil, Revenue ($m), by Sub Segment, 2005-2013 51
4.2.5 Biliary Stents Market, Brazil, Revenue ($m), by Segment, 2013-2020 52
4.2.5.1 Metal Biliary Stents Market, Brazil, Revenue ($m), by Sub Segment, 2013-2020 54
4.2.6 Gastrointestinal Stents Market, Brazil, Revenue ($m), by Segment, 2013-2020 56
4.2.7 Airway Stents Market, Brazil, Revenue ($m), by Segment, 2013-2020 58
4.2.7.1 Metallic Airway Stents Market, Brazil, Revenue ($m), by Sub Segment, 2013-2020 60
4.2.8 Urinary Tract Stents Market, Brazil, Revenue ($m), by Segment, 2013-2020 61
4.2.8.1 Prostate Stents Market, Brazil, Revenue ($m), by Sub Segment, 2013-2020 63
4.2.8.2 Ureteral Stents Market, Brazil, Revenue ($m), by Sub Segment, 2013-2020 64
4.2.8.3 Urethral Stents Market, Brazil, Revenue ($m), by Sub Segment, 2013-2020 65
4.3 Non-Vascular Stents Market, Brazil, Volume (Units), 2005-2013 66
4.4 Non-Vascular Stents Market, Brazil, Volume (Units), 2013-2020 68
4.4.1 Biliary Stents Market, Brazil, Volume (Units), by Segment, 2005-2013 70
4.4.1.1 Metal Biliary Stents Market, Brazil, Volume (Units), by Sub Segment, 2005-2013 72
4.4.2 Gastrointestinal Stents Market, Brazil, Volume (Units), by Segment, 2005-2013 74
4.4.3 Airway Stents Market, Brazil, Volume (Units), by Segment, 2005-2013 76
4.4.3.1 Metallic Airway Stents Market, Brazil, Volume (Units), by Sub Segment, 2005-2013 78
4.4.4 Urinary Tract Stents Market, Brazil, Volume (Units), by Segment, 2005-2013 80
4.4.4.1 Prostate Stents Market, Brazil, Volume (Units), by Sub Segment, 2005-2013 82
4.4.4.2 Ureteral Stents Market, Brazil, Volume (Units), by Sub Segment, 2005-2013 83
4.4.4.3 Urethral Stents Market, Brazil, Volume (Units), by Sub Segment, 2005-2013 84
4.4.5 Biliary Stents Market, Brazil, Volume (Units), by Segment, 2013-2020 85
4.4.5.1 Metal Biliary Stents Market, Brazil, Volume (Units), by Sub Segment, 2013-2020 87
4.4.6 Gastrointestinal Stents Market, Brazil, Volume (Units), by Segment, 2013-2020 89
4.4.7 Airway Stents Market, Brazil, Volume (Units), by Segment, 2013-2020 91
4.4.7.1 Metallic Airway Stents Market, Brazil, Volume (Units), by Sub Segment, 2013-2020 93
4.4.8 Urinary Tract Stents Market, Brazil, Volume (Units), by Segment, 2013-2020 95
4.4.8.1 Prostate Stents Market, Brazil, Volume (Units), by Sub Segment, 2013-2020 97
4.4.8.2 Ureteral Stents Market, Brazil, Volume (Units), by Sub Segment, 2013-2020 98
4.4.8.3 Urethral Stents Market, Brazil, Volume (Units), by Sub Segment, 2013-2020 99
4.5 Non-Vascular Stents Market, Brazil, Average Price ($), 2005-2020 100
4.6 Non-Vascular Stents Market, Brazil, Distribution Share by Revenue ($m), 2012-2013 103
4.7 Non-Vascular Stents Market, Brazil, Company Share by Revenue ($m), 2012-2013 104

5 Non-Vascular Stents Market, Russia 106
5.1 Non-Vascular Stents Market, Russia, Revenue ($m), 2005-2013 106
5.2 Non-Vascular Stents Market, Russia, Revenue ($m), 2013-2020 108
5.2.1 Biliary Stents Market, Russia, Revenue ($m), by Segment, 2005-2013 110
5.2.1.1 Metal Biliary Stents Market, Russia, Revenue ($m), by Sub Segment, 2005-2013 112
5.2.2 Gastrointestinal Stents Market, Russia, Revenue ($m), by Segment, 2005-2013 114
5.2.3 Airway Stents Market, Russia, Revenue ($m), by Segment, 2005-2013 116
5.2.4 Urinary Tract Stents Market, Russia, Revenue ($m), by Segment, 2005-2013 118
5.2.4.1 Prostate Stents Market, Russia, Revenue ($m), by Sub Segment, 2005-2013 120
5.2.4.2 Ureteral Stents Market, Russia, Revenue ($m), by Sub Segment, 2005-2013 121
5.2.4.3 Urethral Stents Market, Russia, Revenue ($m), by Sub Segment, 2005-2013 123
5.2.5 Biliary Stents Market, Russia, Revenue ($m), by Segment, 2013-2020 124
5.2.5.1 Metal Biliary Stents Market, Russia, Revenue ($m), by Sub Segment, 2013-2020 126
5.2.6 Gastrointestinal Stents Market, Russia, Revenue ($m), by Segment, 2013-2020 128
5.2.7 Airway Stents Market, Russia, Revenue ($m), by Segment, 2013-2020 130
5.2.8 Urinary Tract Stents Market, Russia, Revenue ($m), by Segment, 2013-2020 132
5.2.8.1 Prostate Stents Market, Russia, Revenue ($m), by Sub Segment, 2013-2020 134
5.2.8.2 Ureteral Stents Market, Russia, Revenue ($m), by Sub Segment, 2013-2020 135
5.2.8.3 Urethral Stents Market, Russia, Revenue ($m), by Sub Segment, 2013-2020 137
5.3 Non-Vascular Stents Market, Russia, Volume (Units), 2005-2013 139
5.4 Non-Vascular Stents Market, Russia, Volume (Units), 2013-2020 141
5.4.1 Biliary Stents Market, Russia, Volume (Units), by Segment, 2005-2013 143
5.4.1.1 Metal Biliary Stents Market, Russia, Volume (Units), by Sub Segment, 2005-2013 145
5.4.2 Gastrointestinal Stents Market, Russia, Volume (Units), by Segment, 2005-2013 147
5.4.3 Airway Stents Market, Russia, Volume (Units), by Segment, 2005-2013 149
5.4.4 Urinary Tract Stents Market, Russia, Volume (Units), by Segment, 2005-2013 151
5.4.4.1 Prostate Stents Market, Russia, Volume (Units), by Sub Segment, 2005-2013 153
5.4.4.2 Ureteral Stents Market, Russia, Volume (Units), by Sub Segment, 2005-2013 154
5.4.4.3 Urethral Stents Market, Russia, Volume (Units), by Sub Segment, 2005-2013 156
5.4.5 Biliary Stents Market, Russia, Volume (Units), by Segment, 2013-2020 157
5.4.5.1 Metal Biliary Stents Market, Russia, Volume (Units), by Sub Segment, 2013-2020 159
5.4.6 Gastrointestinal Stents Market, Russia, Volume (Units), by Segment, 2013-2020 161
5.4.7 Airway Stents Market, Russia, Volume (Units), by Segment, 2013-2020 163
5.4.8 Urinary Tract Stents Market, Russia, Volume (Units), by Segment, 2013-2020 165
5.4.8.1 Prostate Stents Market, Russia, Volume (Units), by Sub Segment, 2013-2020 167
5.4.8.2 Ureteral Stents Market, Russia, Volume (Units), by Sub Segment, 2013-2020 169
5.4.8.3 Urethral Stents Market, Russia, Volume (Units), by Sub Segment, 2013-2020 171
5.5 Non-Vascular Stents Market, Russia, Average Price ($), 2005-2020 173
5.6 Non-Vascular Stents Market, Russia, Distribution Share by Revenue ($m), 2012-2013 177
5.7 Non-Vascular Stents Market, Russia, Company Share by Revenue ($m), 2012-2013 178

6 Non-Vascular Stents Market, India 180
6.1 Non-Vascular Stents Market, India, Revenue ($m), 2005-2013 180
6.2 Non-Vascular Stents Market, India, Revenue ($m), 2013-2020 182
6.2.1 Biliary Stents Market, India, Revenue ($m), by Segment, 2005-2013 184
6.2.1.1 Metal Biliary Stents Market, India, Revenue ($m), by Sub Segment, 2005-2013 186
6.2.2 Gastrointestinal Stents Market, India, Revenue ($m), by Segment, 2005-2013 188
6.2.3 Airway Stents Market, India, Revenue ($m), by Segment, 2005-2013 190
6.2.3.1 Metallic Airway Stents Market, India, Revenue ($m), by Sub Segment, 2005-2013 192
6.2.4 Urinary Tract Stents Market, India, Revenue ($m), by Segment, 2005-2013 194
6.2.4.1 Prostate Stents Market, India, Revenue ($m), by Sub Segment, 2005-2013 196
6.2.4.2 Ureteral Stents Market, India, Revenue ($m), by Sub Segment, 2005-2013 198
6.2.4.3 Urethral Stents Market, India, Revenue ($m), by Sub Segment, 2005-2013 200
6.2.5 Biliary Stents Market, India, Revenue ($m), by Segment, 2013-2020 202
6.2.5.1 Metal Biliary Stents Market, India, Revenue ($m), by Sub Segment, 2013-2020 204
6.2.6 Gastrointestinal Stents Market, India, Revenue ($m), by Segment, 2013-2020 206
6.2.7 Airway Stents Market, India, Revenue ($m), by Segment, 2013-2020 208
6.2.7.1 Metallic Airway Stents Market, India, Revenue ($m), by Sub Segment, 2013-2020 210
6.2.8 Urinary Tract Stents Market, India, Revenue ($m), by Segment, 2013-2020 212
6.2.8.1 Prostate Stents Market, India, Revenue ($m), by Sub Segment, 2013-2020 214
6.2.8.2 Ureteral Stents Market, India, Revenue ($m), by Sub Segment, 2013-2020 216
6.2.8.3 Urethral Stents Market, India, Revenue ($m), by Sub Segment, 2013-2020 218
6.3 Non-Vascular Stents Market, India, Volume (Units), 2005-2013 220
6.4 Non-Vascular Stents Market, India, Volume (Units), 2013-2020 222
6.4.1 Biliary Stents Market, India, Volume (Units), by Segment, 2005-2013 224
6.4.1.1 Metal Biliary Stents Market, India, Volume (Units), by Sub Segment, 2005-2013 226
6.4.2 Gastrointestinal Stents Market, India, Volume (Units), by Segment, 2005-2013 228
6.4.3 Airway Stents Market, India, Volume (Units), by Segment, 2005-2013 230
6.4.3.1 Metallic Airway Stents Market, India, Volume (Units), by Sub Segment, 2005-2013 232
6.4.4 Urinary Tract Stents Market, India, Volume (Units), by Segment, 2005-2013 234
6.4.4.1 Prostate Stents Market, India, Volume (Units), by Sub Segment, 2005-2013 236
6.4.4.2 Ureteral Stents Market, India, Volume (Units), by Sub Segment, 2005-2013 238
6.4.4.3 Urethral Stents Market, India, Volume (Units), by Sub Segment, 2005-2013 240
6.4.5 Biliary Stents Market, India, Volume (Units), by Segment, 2013-2020 242
6.4.5.1 Metal Biliary Stents Market, India, Volume (Units), by Sub Segment, 2013-2020 244
6.4.6 Gastrointestinal Stents Market, India, Volume (Units), by Segment, 2013-2020 246
6.4.7 Airway Stents Market, India, Volume (Units), by Segment, 2013-2020 248
6.4.7.1 Metallic Airway Stents Market, India, Volume (Units), by Sub Segment, 2013-2020 250
6.4.8 Urinary Tract Stents Market, India, Volume (Units), by Segment, 2013-2020 252
6.4.8.1 Prostate Stents Market, India, Volume (Units), by Sub Segment, 2013-2020 254
6.4.8.2 Ureteral Stents Market, India, Volume (Units), by Sub Segment, 2013-2020 256
6.4.8.3 Urethral Stents Market, India, Volume (Units), by Sub Segment, 2013-2020 258
6.5 Non-Vascular Stents Market, India, Average Price ($), 2005-2020 260
6.6 Non-Vascular Stents Market, India, Distribution Share by Revenue ($m), 2012-2013 264
6.7 Non-Vascular Stents Market, India, Company Share by Revenue ($m), 2012-2013 265

7 Non-Vascular Stents Market, China 267
7.1 Non-Vascular Stents Market, China, Revenue ($m), 2005-2013 267
7.2 Non-Vascular Stents Market, China, Revenue ($m), 2013-2020 269
7.2.1 Biliary Stents Market, China, Revenue ($m), by Segment, 2005-2013 271
7.2.1.1 Metal Biliary Stents Market, China, Revenue ($m), by Sub Segment, 2005-2013 273
7.2.2 Gastrointestinal Stents Market, China, Revenue ($m), by Segment, 2005-2013 275
7.2.3 Airway Stents Market, China, Revenue ($m), by Segment, 2005-2013 277
7.2.3.1 Metallic Airway Stents Market, China, Revenue ($m), by Sub Segment, 2005-2013 279
7.2.4 Urinary Tract Stents Market, China, Revenue ($m), by Segment, 2005-2013 281
7.2.4.1 Prostate Stents Market, China, Revenue ($m), by Sub Segment, 2005-2013 283
7.2.4.2 Ureteral Stents Market, China, Revenue ($m), by Sub Segment, 2005-2013 285
7.2.4.3 Urethral Stents Market, China, Revenue ($m), by Sub Segment, 2005-2013 286
7.2.5 Biliary Stents Market, China, Revenue ($m), by Segment, 2013-2020 287
7.2.5.1 Metal Biliary Stents Market, China, Revenue ($m), by Sub Segment, 2013-2020 289
7.2.6 Gastrointestinal Stents Market, China, Revenue ($m), by Segment, 2013-2020 291
7.2.7 Airway Stents Market, China, Revenue ($m), by Segment, 2013-2020 293
7.2.7.1 Metallic Airway Stents Market, China, Revenue ($m), by Sub Segment, 2013-2020 295
7.2.8 Urinary Tract Stents Market, China, Revenue ($m), by Segment, 2013-2020 297
7.2.8.1 Prostate Stents Market, China, Revenue ($m), by Sub Segment, 2013-2020 299
7.2.8.2 Ureteral Stents Market, China, Revenue ($m), by Sub Segment, 2013-2020 300
7.2.8.3 Urethral Stents Market, China, Revenue ($m), by Sub Segment, 2013-2020 301
7.3 Non-Vascular Stents Market, China, Volume (Units), 2005-2013 302
7.4 Non-Vascular Stents Market, China, Volume (Units), 2013-2020 304
7.4.1 Biliary Stents Market, China, Volume (Units), by Segment, 2005-2013 306
7.4.1.1 Metal Biliary Stents Market, China, Volume (Units), by Sub Segment, 2005-2013 308
7.4.2 Gastrointestinal Stents Market, China, Volume (Units), by Segment, 2005-2013 310
7.4.3 Airway Stents Market, China, Volume (Units), by Segment, 2005-2013 312
7.4.3.1 Metallic Airway Stents Market, China, Volume (Units), by Sub Segment, 2005-2013 314
7.4.4 Urinary Tract Stents Market, China, Volume (Units), by Segment, 2005-2013 316
7.4.4.1 Prostate Stents Market, China, Volume (Units), by Sub Segment, 2005-2013 318
7.4.4.2 Ureteral Stents Market, China, Volume (Units), by Sub Segment, 2005-2013 319
7.4.4.3 Urethral Stents Market, China, Volume (Units), by Sub Segment, 2005-2013 320
7.4.5 Biliary Stents Market, China, Volume (Units), by Segment, 2013-2020 321
7.4.5.1 Metal Biliary Stents Market, China, Volume (Units), by Sub Segment, 2013-2020 323
7.4.6 Gastrointestinal Stents Market, China, Volume (Units), by Segment, 2013-2020 325
7.4.7 Airway Stents Market, China, Volume (Units), by Segment, 2013-2020 327
7.4.7.1 Metallic Airway Stents Market, China, Volume (Units), by Sub Segment, 2013-2020 329
7.4.8 Urinary Tract Stents Market, China, Volume (Units), by Segment, 2013-2020 331
7.4.8.1 Prostate Stents Market, China, Volume (Units), by Sub Segment, 2013-2020 333
7.4.8.2 Ureteral Stents Market, China, Volume (Units), by Sub Segment, 2013-2020 334
7.4.8.3 Urethral Stents Market, China, Volume (Units), by Sub Segment, 2013-2020 335
7.5 Non-Vascular Stents Market, China, Average Price ($), 2005-2020 336
7.6 Non-Vascular Stents Market, China, Distribution Share by Revenue ($m), 2012-2013 340
7.7 Non-Vascular Stents Market, China, Company Share by Revenue ($m), 2012-2013 341

8 Overview of Key Companies in BRIC Non-Vascular Stents Market 343
8.1 Boston Scientific Corporation 343
8.2 Cook Group Incorporated 343
8.3 C. R. Bard, Inc. 343
8.4 Covidien plc 344
8.5 Taewoong Medical Co.,Ltd. 344
8.6 Olympus Corporation 344
8.7 Merit Medical Systems, Inc. 345
8.8 ConMed Corporation 345
8.9 Applied Medical Corporation 345
8.10 Changzhou Ankang Medical Instruments Co., LTD. 346

Browse more reports on Medical Devices Market
http://www.marketoptimizer.org/category/life-sciences/medical-devices

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MarketOptimizer.org adds “Xarelto (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” report to its research database.

Dallas, TX -- (SBWIRE) -- 09/17/2014 -- "Xarelto (Acute Coronary Syndrome) Forecast and Market Analysis to 2023?. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Complete Report Details
http://www.marketoptimizer.org/xarelto-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html

Xarelto was approved in the EU for the prevention of non-valvular atrial fibrillation (AF)-related stroke and systemic embolism, and for the treatment of deep vein thrombosis (DVT). On July 1, 2011, Xarelto was approved in the US to reduce the risk of blood clots, DVT, and pulmonary embolism (PE) following hip or knee replacement surgery, and in November of the same year, it was approved for stroke prevention in patients with non-valvular AF.

Scope:

-Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

-Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.

-Sales forecast for Aricept for the top seven countries from 2013 to 2023.

-Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=10448

Reasons to buy:

-Understand and capitalize by identifying products that are most likely to ensure a robust return

-Stay ahead of the competition by understanding the changing competitive landscape for ACS

-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

-Make more informed business decisions from insightful and in-depth analysis of Aricept performance

-Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents For This Report

Table of Contents

1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 11

2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
2.3 Upcoming Related Reports 15

3 Disease Overview 16
3.1 Etiology and Pathophysiology 17
3.1.1 Etiology 17
3.1.2 Pathophysiology 21
3.1.3 Prognosis 22
3.1.4 Quality of Life 23
3.2 Symptoms 23

4 Disease Management 25
4.1 Treatment Overview 25

5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitor Assessment 32

6 Unmet Need and Opportunity 37
6.1 Overview 37
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 38
6.2.1 Unmet Need 38
6.2.2 Gap Analysis 39
6.2.3 Opportunity 39
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 40
6.3.1 Unmet Need 40
6.3.2 Gap Analysis 41
6.3.3 Opportunity 41
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 42
6.4.1 Unmet Need 42
6.4.2 Gap Analysis 44
6.4.3 Opportunity 46
6.5 Antidotes for New Oral Anticoagulants (NOACs) 46
6.5.1 Unmet Need 46
6.5.2 Gap Analysis 47
6.5.3 Opportunity 47
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 48
6.6.1 Unmet Need 48
6.6.2 Gap Analysis 49
6.6.3 Opportunity 49

7 Pipeline Assessment 51
7.1 Overview 51
7.2 Clinical Trials by Phase and Trial Status 53
7.3 Promising Drugs in Clinical Development 55

8 Xarelto (rivaroxaban) 60
8.1 Overview 60
8.2 Efficacy 63
8.3 Safety 65
8.4 Dosing and Formulation 65
8.5 Potential Clinical Positioning 65
8.6 Potential Commercial Positioning 66
8.7 Pricing and Reimbursement 66
8.8 SWOT Analysis 67
8.9 Forecast 67

9 Appendix 70
9.1 Bibliography 70
9.2 Abbreviations 76
9.3 Methodology 80
9.4 Forecasting Methodology 80
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 80
9.4.2 Diagnosed Acute Coronary Syndrome Patients 81
9.4.3 Percent Drug-Treated Patients 82
9.4.4 General Pricing Assumptions 82
9.4.5 Generic Erosion 84
9.4.6 Pricing of Pipeline Agents 84
9.5 Physicians and Specialists Included in this Study 85
9.6 About the Authors 88
9.6.1 Author 88
9.6.2 Reviewer 88
9.6.3 Global Head of Healthcare 89
9.7 About GlobalData 90
9.8 Disclaimer 90

Browse more reports on Pharmaceuticals Market
http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MarketOptimizer.org adds “Alirocumab (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” report to its research database.

Dallas, TX -- (SBWIRE) -- 09/16/2014 -- "Zontivity (Acute Coronary Syndrome) Forecast and Market Analysis to 2023?. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Under normal circumstances, thrombin proteolytically processes the platelet surface receptor protein PAR1, which initiates a strong platelet-activating, pro-thrombotic, signal transduction pathway. Zontivity locks the PAR1 receptor into a conformation that prevents thrombin recognition, thereby halting platelet activation and thrombosis at this key step. Of the several receptor-mediated platelet activation pathways, the PAR1 route results in a particularly strong platelet activation response.

Complete Report Details
http://www.marketoptimizer.org/zontivity-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html

Scope:

-Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

-Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.

-Sales forecast for Aricept for the top seven countries from 2013 to 2023.

-Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy:

-Understand and capitalize by identifying products that are most likely to ensure a robust return

-Stay ahead of the competition by understanding the changing competitive landscape for ACS

-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

-Make more informed business decisions from insightful and in-depth analysis of Aricept performance

-Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=10451

Table of Contents For This Report

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14

3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.1.3 Prognosis 21
3.1.4 Quality of Life 22
3.2 Symptoms 22

4 Disease Management 24
4.1 Treatment Overview 24

5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31

6 Unmet Need and Opportunity 36
6.1 Overview 36
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 37
6.2.1 Unmet Need 37
6.2.2 Gap Analysis 38
6.2.3 Opportunity 38
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 43
6.4.3 Opportunity 45
6.5 Antidotes for New Oral Anticoagulants (NOACs) 45
6.5.1 Unmet Need 45
6.5.2 Gap Analysis 46
6.5.3 Opportunity 46
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 47
6.6.1 Unmet Need 47
6.6.2 Gap Analysis 48
6.6.3 Opportunity 48

7 Pipeline Assessment 50
7.1 Overview 50
7.2 Clinical Trials by Phase and Trial Status 52
7.3 Promising Drugs in Clinical Development 54

8 Alirocumab (RGN727) 59
8.1 Overview 59
8.2 Efficacy 62
8.3 Safety 64
8.4 Dosing and Formulation 64
8.5 Potential Clinical Positioning 65
8.6 Potential Commercial Positioning 65
8.7 Pricing and Reimbursement 66
8.8 SWOT Analysis 67
8.9 Forecast 67

9 Appendix 69
9.1 Bibliography 69
9.2 Abbreviations 76
9.3 Methodology 80
9.4 Forecasting Methodology 80
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 80
9.4.2 Diagnosed Acute Coronary Syndrome Patients 81
9.4.3 Percent Drug-Treated Patients 82
9.4.4 General Pricing Assumptions 82
9.4.5 Generic Erosion 84
9.4.6 Pricing of Pipeline Agents 84
9.5 Physicians and Specialists Included in this Study 85
9.6 About the Authors 88
9.6.1 Author 88
9.6.2 Reviewer 88
9.6.3 Global Head of Healthcare 89
9.7 About GlobalData 90
9.8 Disclaimer 90

Browse more reports on Pharmaceuticals Market
http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MarketOptimizer.org adds “Zontivity (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” report to its research database.

Dallas, TX -- (SBWIRE) -- 09/16/2014 -- "Zontivity (Acute Coronary Syndrome) Forecast and Market Analysis to 2023?. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Under normal circumstances, thrombin proteolytically processes the platelet surface receptor protein PAR1, which initiates a strong platelet-activating, pro-thrombotic, signal transduction pathway. Zontivity locks the PAR1 receptor into a conformation that prevents thrombin recognition, thereby halting platelet activation and thrombosis at this key step. Of the several receptor-mediated platelet activation pathways, the PAR1 route results in a particularly strong platelet activation response.

Complete Report Details
http://www.marketoptimizer.org/zontivity-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html

Scope:

-Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

-Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.

-Sales forecast for Aricept for the top seven countries from 2013 to 2023.

-Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy:

-Understand and capitalize by identifying products that are most likely to ensure a robust return

-Stay ahead of the competition by understanding the changing competitive landscape for ACS

-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

-Make more informed business decisions from insightful and in-depth analysis of Aricept performance

-Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=10450

Table of Contents For This Report

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14

3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.1.3 Prognosis 21
3.1.4 Quality of Life 22
3.2 Symptoms 22

4 Disease Management 24
4.1 Treatment Overview 24

5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31

6 Unmet Need and Opportunity 36
6.1 Overview 36
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 37
6.2.1 Unmet Need 37
6.2.2 Gap Analysis 38
6.2.3 Opportunity 38
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 43
6.4.3 Opportunity 45
6.5 Antidotes for New Oral Anticoagulants (NOACs) 45
6.5.1 Unmet Need 45
6.5.2 Gap Analysis 46
6.5.3 Opportunity 46
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 47
6.6.1 Unmet Need 47
6.6.2 Gap Analysis 48
6.6.3 Opportunity 48

7 Pipeline Assessment 50
7.1 Overview 50
7.2 Clinical Trials by Phase and Trial Status 52
7.3 Promising Drugs in Clinical Development 54

8 Zontivity (vorapaxar) 59
8.1 Overview 59
8.2 Efficacy 61
8.3 Safety 62
8.4 Dosing and Formulation 63
8.5 Potential Clinical Positioning 63
8.6 Potential Commercial Positioning 63
8.7 Pricing and Reimbursement 64
8.8 SWOT Analysis 65
8.9 Forecast 65

9 Appendix 67
9.1 Bibliography 67
9.2 Abbreviations 73
9.3 Methodology 77
9.4 Forecasting Methodology 77
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 77
9.4.2 Diagnosed Acute Coronary Syndrome Patients 78
9.4.3 Percent Drug-Treated Patients 79
9.4.4 General Pricing Assumptions 79
9.4.5 Generic Erosion 81
9.4.6 Pricing of Pipeline Agents 81
9.5 Physicians and Specialists Included in this Study 82
9.6 About the Authors 85
9.6.1 Author 85
9.6.2 Reviewer 85
9.6.3 Global Head of Healthcare 86
9.7 About GlobalData 87
9.8 Disclaimer 87

Browse more reports on Pharmaceuticals Market
http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MarketOptimizer.org adds “North America Non-Vascular Stents Market Outlook to 2020” report to its research database.

Dallas, TX -- (SBWIRE) -- 09/15/2014 -- "North America Non-Vascular Stents Market Outlook to 2020, provides key market data on the North America Non-Vascular Stents market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments –
- Biliary Stents (Plastic Biliary Stents and Metal Biliary Stents (Metal Non-Covered Biliary Stents, Metal Partially Covered Biliary Stents and Metal Fully Covered Biliary Stents))
- Gastrointestinal Stents (Fully Covered, Partially Covered and Non-Covered Gastrointestinal Stents)
- Airway Stents (Silicone Airway Stents and Metallic Airway Stents (Fully Covered and Uncovered Metallic Airway Stents) and Urinary Tract Stents ((Ureteral Stents (Metal, Polymer and Bioabsorbable Ureteral Stents)
- Prostate Stents (Metal, Polymer and Bioabsorbable Prostate Stents) and Urethral Stents (Metal, Polymer and Bioabsorbable Urethral Stents))

Complete Report Details @ http://www.marketoptimizer.org/north-america-non-vascular-stents-market-outlook-to-2020.html.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Non-Vascular Stents market wherever available.

The data in the report is derived from dynamic market forecast models. Epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Order a Purchase copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10485 .

Overview of Key Companies in North America Non-Vascular Stents Market:
- Boston Scientific Corporation
- Cook Group Incorporated
- C. R. Bard, Inc.
- Covidien plc
- Taewoong Medical Co.,Ltd.
- Applied Medical Corporation
- Olympus Corporation
- ConMed Corporation

Scope
- Market size data for Non-Vascular Stents market segments – Biliary Stents (Plastic Biliary Stents and Metal Biliary Stents (Metal Non-Covered Biliary Stents, Metal Partially Covered Biliary Stents and Metal Fully Covered Biliary Stents)), Gastrointestinal Stents (Fully Covered, Partially Covered and Non-Covered Gastrointestinal Stents), Airway Stents (Silicone Airway Stents and Metallic Airway Stents (Fully Covered and Uncovered Metallic Airway Stents) and Urinary Tract Stents ((Ureteral Stents (Metal, Polymer and Bioabsorbable Ureteral Stents), Prostate Stents (Metal, Polymer and Bioabsorbable Prostate Stents) and Urethral Stents (Metal, Polymer and Bioabsorbable Urethral Stents)).
- Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.
- 2013 company shares and distribution shares data for Non-Vascular Stents market.
- Global corporate-level profiles of key companies operating within the Non-Vascular Stents market.
- Key players covered include Boston Scientific, Taewoong Medical, Merit Medical, Cook Medical, PNN Medical, Teleflex, Inc. and C.R. Bard.

Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

Browse more reports on Medical Devices Market @ http://www.marketoptimizer.org/category/life-sciences/medical-devices.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MarketOptimizer.org adds “Canada Non-Vascular Stents Market Outlook to 2020” report to its research database.

Dallas, TX -- (SBWIRE) -- 09/15/2014 -- "Canada Non-Vascular Stents Market Outlook to 2020?, provides key market data on the Canada Non-Vascular Stents market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments – Biliary Stents (Plastic Biliary Stents and Metal Biliary Stents (Metal Non-Covered Biliary Stents, Metal Partially Covered Biliary Stents and Metal Fully Covered Biliary Stents)), Gastrointestinal Stents (Fully Covered, Partially Covered and Non-Covered Gastrointestinal Stents), Airway Stents (Silicone Airway Stents and Metallic Airway Stents (Fully Covered and Uncovered Metallic Airway Stents) and Urinary Tract Stents (Ureteral Stents (Metal, Polymer and Bioabsorbable Ureteral Stents), Prostate Stents (Metal, Polymer and Bioabsorbable Prostate Stents) and Urethral Stents (Metal, Polymer and Bioabsorbable Urethral Stents).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Non-Vascular Stents market wherever available.

Complete Report Details @ http://www.marketoptimizer.org/canada-non-vascular-stents-market-outlook-to-2020.html .

The data in the report is derived from dynamic market forecast models. Epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=10482

Overview of Key Companies in Canada, Non-Vascular Stents Market:

- Boston Scientific Corporation
- Cook Group Incorporated
- C. R. Bard, Inc.
- Taewoong Medical Co.,Ltd.
- Olympus Corporation
- ConMed Corporation
- Covidien plc
- Applied Medical Corporation

Scope:

-Market size data for Non-Vascular Stents market segments – Biliary Stents (Plastic Biliary Stents and Metal Biliary Stents (Metal Non-Covered Biliary Stents, Metal Partially Covered Biliary Stents and Metal Fully Covered Biliary Stents)), Gastrointestinal Stents (Fully Covered, Partially Covered and Non-Covered Gastrointestinal Stents), Airway Stents (Silicone Airway Stents and Metallic Airway Stents (Fully Covered and Uncovered Metallic Airway Stents) and Urinary Tract Stents (Ureteral Stents (Metal, Polymer and Bioabsorbable Ureteral Stents), Prostate Stents (Metal, Polymer and Bioabsorbable Prostate Stents) and Urethral Stents (Metal, Polymer and Bioabsorbable Urethral Stents).

-Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.

-2013 company shares and distribution shares data for Non-Vascular Stents market.

-Global corporate-level profiles of key companies operating within the Non-Vascular Stents market.

-Key players covered include Boston Scientific, Taewoong Medical, Merit Medical, Cook Medical, PNN Medical, Teleflex, Inc. and C.R. Bard.

Reasons to buy:

- Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution
- Identify, understand and capitalize.

Browse more reports on Medical Devices Market
http://www.marketoptimizer.org/category/life-sciences/medical-devices

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MarketOptimizer.org adds “Heart Valve Disease Global Clinical Trials Review, H2, 2014” report to its research database.

Dallas, TX -- (SBWIRE) -- 09/12/2014 -- "Heart Valve Disease Global Clinical Trials Review, H2, 2014? provides data on the Heart Valve Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Heart Valve Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Heart Valve Disease.

A heart valve normally allows blood to flow in only one direction through the heart. The four valves commonly represented in a mammalian heart determine the pathway of blood flow through the heart. A heart valve opens or closes incumbent upon differential blood pressure on each side.

Complete Report Details
http://www.marketoptimizer.org/heart-valve-disease-global-clinical-trials-review-h2-2014.html

The four main valves in the heart are:

-The two atrioventricular (AV) valves, the mitral valve (bicuspid valve), and the tricuspid valve, which are between the upper atria and the lower ventricles.

-The two semilunar (SL) valves, the aortic valve and the pulmonary valve, which are in the arteries leaving the heart.

The mitral valve and the aortic valve are in the left heart and the tricuspid valve and the pulmonary valve are in the right heart.

Scope:

-Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations

-Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

-Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons To Buy:

-Understand the dynamics of a particular indication in a condensed manner
-Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
-Obtain discontinued trial listing for trials across the globe
-Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=10425

Scope:

-Market size data for Bronchoscopes market segments – Video Bronchoscopes (Flexible Video Bronchoscopes and Portable Video Bronchoscopes) and Non-Video Bronchoscopes (Rigid Non-Video Bronchoscopes and Flexible Non-Video (Fibre) Bronchoscopes).

-Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.

-2013 company shares and distribution shares data for Bronchoscopes market.

-Global corporate-level profiles of key companies operating within the Spain Bronchoscopes market.

-Key players covered include Olympus Corporation, Hoya Corporation, Fujifilm Holdings Corporation and KARL STORZ GmbH & Co. KG.

Reasons to buy:

-Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.

-Develop market-entry and market expansion strategies.

-Design competition strategies by identifying who-stands-where in the market.

-Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

-What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

Browse more reports on Pharmaceuticals Market
http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MarketOptimizer.org adds “Spain Bronchoscopes Market Outlook to 2020” report to its research database.

Dallas, TX -- (SBWIRE) -- 09/10/2014 -- "Spain Bronchoscopes Market Outlook to 2020?, provides key market data on the Spain Bronchoscopes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments – Video Bronchoscopes (Flexible Video Bronchoscopes and Portable Video Bronchoscopes) and Non-Video Bronchoscopes (Rigid Non-Video Bronchoscopes and Flexible Non-Video (Fibre) Bronchoscopes).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Bronchoscopes market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Complete Report Details
http://www.marketoptimizer.org/spain-bronchoscopes-market-outlook-to-2020.html

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Overview of Key Companies in Spain, Bronchoscopes Market:
- Olympus Corporation
- PENTAX Medical Company
- KARL STORZ GmbH & Co. KG
- Richard Wolf GmbH
- Fujifilm Holdings Corporation

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=10371

Scope:

-Market size data for Bronchoscopes market segments – Video Bronchoscopes (Flexible Video Bronchoscopes and Portable Video Bronchoscopes) and Non-Video Bronchoscopes (Rigid Non-Video Bronchoscopes and Flexible Non-Video (Fibre) Bronchoscopes).

-Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020.

-2013 company shares and distribution shares data for Bronchoscopes market.

-Global corporate-level profiles of key companies operating within the Spain Bronchoscopes market.

-Key players covered include Olympus Corporation, Hoya Corporation, Fujifilm Holdings Corporation and KARL STORZ GmbH & Co. KG.

Reasons to buy:

-Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.

-Develop market-entry and market expansion strategies.

-Design competition strategies by identifying who-stands-where in the market.

-Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

-What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

Browse more reports on Medical Devices Market
http://www.marketoptimizer.org/category/life-sciences/medical-devices

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm